ArticleDrug delivery and translational research2026
Cyclodextrin-based MOFs for oral delivery of fingolimod with enhanced pharmacokinetics.
Article in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study is aimed to improve the pharmacologically important properties of fingolimod – an immunomodulatory drug for multiple sclerosis treatment. Cyclodextrin-based metal-organic frameworks (CD-MOFs) were considered as advanced biocompatible delivery systems, which are able to increase the aqueous solubility, dissolution rate and pharmacokinetics of lipophilic fingolimod. CD-MOFs synthesized on the basis of K+ cations and native α-, β- and γ-cyclodextrins differ in structure and properties. In this work, the influence of surface area, pore dimensions and particle size of CD-MOFs on their capability to fingolimod encapsulation was analyzed for the first time. It was shown that loading of fingolimod into γCD-MOF is more effective compared with αCD-MOF and βCD-MOF. Adsorption of fingolimod on all CD-MOFs under study is a physical process, mechanism of which depends on the CD-MOF porosity. Adsorption of fingolimod on βCD-MOF possessing low surface area is well described by the Langmuir model, whereas the Freundlich model better simulates the fingolimod adsorption on αCD-MOF and γCD-MOF having highly developed surface area. Crystallization of fingolimod in αCD-MOF displaying higher surface area and pore radius was detected; while the drug fully integrates into βCD-MOF and γCD-MOF, causing the disappearance of the drug crystalline phase. Loading in CD-MOF increases the thermal stability of fingolimod. Moreover, in vitro release study showed that dissolution rate of fingolimod loaded into CD-MOFs is considerably increased in phosphate buffer (pH = 6.8). The in vivo experiments showed that bioavailability of orally administrated fingolimod can be improved via encapsulation in γCD-MOF. The obtained results confirm the feasibility of CD-MOFs in design of novel dosage forms of fingolimod for oral administration.
Indexed as
Identifiers
42050313What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.